Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMURF2 | Q9HAU4 | 1/20 | 0.33 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23062882 | 0.85 | BRD4 (0.40) | BRD4LMNAKMT2AMEN1GAA | |
| SCHEMBL23082837 | 0.80 | BRD4 (0.37) | BRD4LMNAKMT2AMEN1GAA | |
| SCHEMBL23062934 | 0.80 | BRD4 (0.37) | BRD4LMNASMN1; SMN2RECQLPOLB | |
| SCHEMBL6889091 | 0.79 | RECQL (0.43) | MAPTLMNAKMT2AMEN1GAA | |
| SCHEMBL5736534 | 0.77 | ALDH1A1 (0.41) | BRD4LMNAKMT2AGAARECQL | |
| SCHEMBL23062948 | 0.77 | BRD4 (0.36) | BRD4LMNARECQLPOLBHTT | |
| SCHEMBL11520965 | 0.76 | ALDH1A1 (0.40) | BRD4LMNAKMT2AGAARECQL | |
| SCHEMBL10279301 | 0.75 | LMNA (0.39) | MAPTLMNAKMT2AMEN1GAA | |
| SCHEMBL16104449 | 0.74 | HSD17B10 (0.36) | BRD4MAPTLMNAPOLBNPSR1 | |
| SCHEMBL12180942 | 0.74 | HSD17B10 (0.36) | BRD4MAPTLMNAPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119076-B | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东有限责任公司 | 2025-01-10 | — | — | CN | disclosed |
| EP-3788043-B1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME LLC (US) | 2024-11-06 | — | — | EP | disclosed |
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | MERCK SHARP & DOHME CORP. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210070745-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | MERCK SHARP & DOHME CORP. (US) | 2021-03-11 | — | — | US | disclosed |
| EP-3788043-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | Merck Sharp & Dohme Corp. (US) | 2021-03-10 | — | — | EP | disclosed |
| CN-112119076-A | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | 默沙东公司 | 2020-12-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332463-B2 | Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors | CHRNA7, CHRNA5, CHRNA6 | BRD4 1627/4885MAPT 508/4885LMNA 4621/4885 |
| US-20210070745-A1 | SPIROPIPERIDINE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA7, CHRNA5, CHRNA6 | BRD4 1627/4885MAPT 508/4885LMNA 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.